Intercept Pharma (ICPT) Misses Q4 EPS by 37c

Intercept Pharma (NASDAQ: ICPT) reported Q4 EPS of ($2.99), $0.37 worse than the analyst estimate of ($2.62). Revenue for the quarter came in at $71.5 million versus the consensus estimate of $68.42 million.

For earnings history and earnings-related data on Intercept Pharma (ICPT) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Gemini Space Station, Inc. (GEMI) Misses Q2 EPS by 32c
• Kodiak Sciences Inc. (KOD) Misses Q2 EPS by 7c